Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
1.
Nat Commun ; 15(1): 4584, 2024 May 29.
Article in English | MEDLINE | ID: mdl-38811577

ABSTRACT

Stimulator of interferon genes (STING) is a central component of the cytosolic nucleic acids sensing pathway and as such master regulator of the type I interferon response. Due to its critical role in physiology and its' involvement in a variety of diseases, STING has been a focus for drug discovery. Targeted protein degradation (TPD) has emerged as a promising pharmacology for targeting previously considered undruggable proteins by hijacking the cellular ubiquitin proteasome system (UPS) with small molecules. Here, we identify AK59 as a STING degrader leveraging HERC4, a HECT-domain E3 ligase. Additionally, our data reveals that AK59 is effective on the common pathological STING mutations, suggesting a potential clinical application of this mechanism. Thus, these findings introduce HERC4 to the fields of TPD and of compound-induced degradation of STING, suggesting potential therapeutic applications.


Subject(s)
Membrane Proteins , Proteolysis , Ubiquitin-Protein Ligases , Ubiquitin-Protein Ligases/metabolism , Ubiquitin-Protein Ligases/genetics , Humans , Membrane Proteins/metabolism , Membrane Proteins/genetics , Proteolysis/drug effects , HEK293 Cells , Animals , Mutation , Proteasome Endopeptidase Complex/metabolism , Ubiquitination
2.
Cell Stem Cell ; 31(4): 554-569.e17, 2024 Apr 04.
Article in English | MEDLINE | ID: mdl-38579685

ABSTRACT

The YAP/Hippo pathway is an organ growth and size regulation rheostat safeguarding multiple tissue stem cell compartments. LATS kinases phosphorylate and thereby inactivate YAP, thus representing a potential direct drug target for promoting tissue regeneration. Here, we report the identification and characterization of the selective small-molecule LATS kinase inhibitor NIBR-LTSi. NIBR-LTSi activates YAP signaling, shows good oral bioavailability, and expands organoids derived from several mouse and human tissues. In tissue stem cells, NIBR-LTSi promotes proliferation, maintains stemness, and blocks differentiation in vitro and in vivo. NIBR-LTSi accelerates liver regeneration following extended hepatectomy in mice. However, increased proliferation and cell dedifferentiation in multiple organs prevent prolonged systemic LATS inhibition, thus limiting potential therapeutic benefit. Together, we report a selective LATS kinase inhibitor agonizing YAP signaling and promoting tissue regeneration in vitro and in vivo, enabling future research on the regenerative potential of the YAP/Hippo pathway.


Subject(s)
Protein Kinase Inhibitors , Protein Serine-Threonine Kinases , YAP-Signaling Proteins , Animals , Humans , Mice , Cell Proliferation , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/metabolism , Stem Cells/metabolism , Transcription Factors/metabolism , YAP-Signaling Proteins/agonists , YAP-Signaling Proteins/drug effects , YAP-Signaling Proteins/metabolism , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology
4.
Cell Rep ; 42(9): 113056, 2023 09 26.
Article in English | MEDLINE | ID: mdl-37651229

ABSTRACT

Suppression of premature termination codons (PTCs) by translational readthrough is a promising strategy to treat a wide variety of severe genetic diseases caused by nonsense mutations. Here, we present two potent readthrough promoters-NVS1.1 and NVS2.1-that restore substantial levels of functional full-length CFTR and IDUA proteins in disease models for cystic fibrosis and Hurler syndrome, respectively. In contrast to other readthrough promoters that affect stop codon decoding, the NVS compounds stimulate PTC suppression by triggering rapid proteasomal degradation of the translation termination factor eRF1. Our results show that this occurs by trapping eRF1 in the terminating ribosome, causing ribosome stalls and subsequent ribosome collisions, and activating a branch of the ribosome-associated quality control network, which involves the translational stress sensor GCN1 and the catalytic activity of the E3 ubiquitin ligases RNF14 and RNF25.


Subject(s)
Cystic Fibrosis , Protein Biosynthesis , Humans , Codon, Terminator/metabolism , Codon, Nonsense , Ribosomes/metabolism , Cystic Fibrosis/genetics
5.
Sci Signal ; 16(768): eabh1083, 2023 01 17.
Article in English | MEDLINE | ID: mdl-36649377

ABSTRACT

Inflammasomes are intracellular protein complexes that promote an inflammatory host defense in response to pathogens and damaged or neoplastic tissues and are implicated in inflammatory disorders and therapeutic-induced toxicity. We investigated the mechanisms of activation for inflammasomes nucleated by NOD-like receptor (NLR) protiens. A screen of a small-molecule library revealed that several tyrosine kinase inhibitors (TKIs)-including those that are clinically approved (such as imatinib and crizotinib) or are in clinical trials (such as masitinib)-activated the NLRP3 inflammasome. Furthermore, imatinib and masitinib caused lysosomal swelling and damage independently of their kinase target, leading to cathepsin-mediated destabilization of myeloid cell membranes and, ultimately, cell lysis that was accompanied by potassium (K+) efflux, which activated NLRP3. This effect was specific to primary myeloid cells (such as peripheral blood mononuclear cells and mouse bone marrow-derived dendritic cells) and did not occur in other primary cell types or various cell lines. TKI-induced lytic cell death and NLRP3 activation, but not lysosomal damage, were prevented by stabilizing cell membranes. Our findings reveal a potential immunological off-target of some TKIs that may contribute to their clinical efficacy or to their adverse effects.


Subject(s)
Inflammasomes , NLR Family, Pyrin Domain-Containing 3 Protein , Mice , Animals , Inflammasomes/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Imatinib Mesylate , Leukocytes, Mononuclear/metabolism , Cell Death , Myeloid Cells/metabolism , Interleukin-1beta/metabolism
6.
Microbiol Res ; 199: 10-18, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28454705

ABSTRACT

The budding yeast S. cerevisiae is widely used as a eukaryotic model organism to elucidate the mechanism of action of low molecular weight compounds. This report describes the development of two high throughput screening methods based on cell viability either by monitoring the reduction of alamarBlue® (resazurin) or by direct optical measurement of cell growth. Both methods can be miniaturized to allow screening of large numbers of samples, and can be performed using S. cerevisiae in 384 and 1536-well format. The alamarBlue® approach achieves Z' values of >0.7 with signal to basal ratios of >6.5, and around 1.1 million low molecular weight compounds were screened, identifying approximately 25,000 primary hits. Dose response curves generated for a subset (1930) using both alamarBlue® and optical density methods showed significant overlap. In genome-wide haploinsufficiency profiling (HIP), 572 of these hits demonstrated a diverse mechanism of action, affecting >25% of all yeast strains.


Subject(s)
Drug Discovery/methods , High-Throughput Screening Assays/methods , Saccharomyces cerevisiae/chemistry , Drug Evaluation, Preclinical/methods , Models, Theoretical , Oxazines/analysis , Saccharomyces cerevisiae/drug effects , Saccharomyces cerevisiae/growth & development , Saccharomycetales/chemistry , Saccharomycetales/drug effects , Saccharomycetales/growth & development , Xanthenes/analysis
7.
SLAS Discov ; 22(5): 571-582, 2017 06.
Article in English | MEDLINE | ID: mdl-28345372

ABSTRACT

Oral and intestinal mucositis is a debilitating side effect of radiation treatment. A mouse model of radiation-induced mucositis leads to weight loss and tissue damage, reflecting the human ailment as it responds to keratinocyte growth factor (KGF), the standard-of-care treatment. Cultured intestinal crypt organoids allowed the development of an assay monitoring the effect of treatments of intestinal epithelium to radiation-induced damage. This in vitro assay resembles the mouse model as KGF and roof plate-specific spondin-1 (RSPO1) enhanced crypt organoid recovery following radiation. Screening identified compounds that increased the survival of organoids postradiation. Testing of these compounds revealed that the organoids changed their responses over time. Unbiased transcriptome analysis was performed on crypt organoid cultures at various time points in culture to investigate this adaptive behavior. A number of genes and pathways were found to be modulated over time, providing a rationale for the altered sensitivity of the organoid cultures. This report describes an in vitro assay that reflects aspects of human disease. The assay was used to identify bioactive compounds, which served as probes to interrogate the biology of crypt organoids over prolonged culture. The pathways that are changing over time may offer potential targets for treatment of mucositis.


Subject(s)
Drug Screening Assays, Antitumor/methods , Intestines/drug effects , Organoids/drug effects , Animals , Cell Culture Techniques/methods , Fibroblast Growth Factor 7/metabolism , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Mice , Mice, Inbred C57BL , Organoids/metabolism , Thrombospondins/metabolism , Transcriptome/physiology
8.
SLAS Discov ; 22(3): 238-249, 2017 03.
Article in English | MEDLINE | ID: mdl-27899692

ABSTRACT

High-throughput screening generates large volumes of heterogeneous data that require a diverse set of computational tools for management, processing, and analysis. Building integrated, scalable, and robust computational workflows for such applications is challenging but highly valuable. Scientific data integration and pipelining facilitate standardized data processing, collaboration, and reuse of best practices. We describe how Jenkins-CI, an "off-the-shelf," open-source, continuous integration system, is used to build pipelines for processing images and associated data from high-content screening (HCS). Jenkins-CI provides numerous plugins for standard compute tasks, and its design allows the quick integration of external scientific applications. Using Jenkins-CI, we integrated CellProfiler, an open-source image-processing platform, with various HCS utilities and a high-performance Linux cluster. The platform is web-accessible, facilitates access and sharing of high-performance compute resources, and automates previously cumbersome data and image-processing tasks. Imaging pipelines developed using the desktop CellProfiler client can be managed and shared through a centralized Jenkins-CI repository. Pipelines and managed data are annotated to facilitate collaboration and reuse. Limitations with Jenkins-CI (primarily around the user interface) were addressed through the selection of helper plugins from the Jenkins-CI community.


Subject(s)
Algorithms , Image Processing, Computer-Assisted/statistics & numerical data , Molecular Imaging/statistics & numerical data , User-Computer Interface , Animals , Cell Line , Gene Expression Regulation , Humans , Internet , Molecular Imaging/methods , Phosphoproteins/antagonists & inhibitors , Phosphoproteins/genetics , Phosphoproteins/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Workflow
9.
BMC Genomics ; 17: 309, 2016 Apr 27.
Article in English | MEDLINE | ID: mdl-27121005

ABSTRACT

BACKGROUND: Hearing loss is the most common sensory defect afflicting several hundred million people worldwide. In most cases, regardless of the original cause, hearing loss is related to the degeneration and death of hair cells and their associated spiral ganglion neurons. Despite this knowledge, relatively few studies have reported regeneration of the auditory system. Significant gaps remain in our understanding of the molecular mechanisms underpinning auditory function, including the factors required for sensory cell regeneration. Recently, the identification of transcriptional activators and repressors of hair cell fate has been augmented by the discovery of microRNAs (miRNAs) associated with hearing loss. As miRNAs are central players of differentiation and cell fate, identification of miRNAs and their gene targets may reveal new pathways for hair cell regeneration, thereby providing new avenues for the treatment of hearing loss. RESULTS: In order to identify new genetic elements enabling regeneration of inner ear sensory hair cells, next-generation miRNA sequencing (miRSeq) was used to identify the most prominent miRNAs expressed in the mouse embryonic inner ear cell line UB/OC-1 during differentiation towards a hair cell like phenotype. Based on these miRSeq results eight most differentially expressed miRNAs were selected for further characterization. In UB/OC-1, miR-210 silencing in vitro resulted in hair cell marker expression, whereas ectopic expression of miR-210 resulted in new hair cell formation in cochlear explants. Using a lineage tracing mouse model, transdifferentiation of supporting epithelial cells was identified as the likely mechanism for this new hair cell formation. Potential miR-210 targets were predicted in silico and validated experimentally using a miR-trap approach. CONCLUSION: MiRSeq followed by ex vivo validation revealed miR-210 as a novel factor driving transdifferentiation of supporting epithelial cells to sensory hair cells suggesting that miR-210 might be a potential new factor for hearing loss therapy. In addition, identification of inner ear pathways regulated by miR-210 identified potential new drug targets for the treatment of hearing loss.


Subject(s)
Cell Transdifferentiation , Hair Cells, Auditory, Inner/cytology , MicroRNAs/metabolism , Organ of Corti/cytology , Regeneration , Animals , Cell Line , Gene Knock-In Techniques , High-Throughput Nucleotide Sequencing , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Transgenic , MicroRNAs/genetics , Organ Culture Techniques , SOXB1 Transcription Factors/genetics , Sequence Analysis, RNA
10.
Expert Opin Drug Discov ; 11(4): 415-23, 2016.
Article in English | MEDLINE | ID: mdl-26924521

ABSTRACT

INTRODUCTION: High throughput screening has become a basic technique with which to explore biological systems. Advances in technology, including increased screening capacity, as well as methods that generate multiparametric readouts, are driving the need for improvements in the analysis of data sets derived from such screens. AREAS COVERED: This article covers the recent advances in the analysis of high throughput screening data sets from arrayed samples, as well as the recent advances in the analysis of cell-by-cell data sets derived from image or flow cytometry application. Screening multiple genomic reagents targeting any given gene creates additional challenges and so methods that prioritize individual gene targets have been developed. The article reviews many of the open source data analysis methods that are now available and which are helping to define a consensus on the best practices to use when analyzing screening data. EXPERT OPINION: As data sets become larger, and more complex, the need for easily accessible data analysis tools will continue to grow. The presentation of such complex data sets, to facilitate quality control monitoring and interpretation of the results will require the development of novel visualizations. In addition, advanced statistical and machine learning algorithms that can help identify patterns, correlations and the best features in massive data sets will be required. The ease of use for these tools will be important, as they will need to be used iteratively by laboratory scientists to improve the outcomes of complex analyses.


Subject(s)
Drug Discovery/methods , Flow Cytometry/methods , High-Throughput Screening Assays/methods , Algorithms , Genomics , Humans , Machine Learning , Quality Control
11.
Nat Chem Biol ; 11(12): 958-66, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26479441

ABSTRACT

High-throughput screening (HTS) is an integral part of early drug discovery. Herein, we focused on those small molecules in a screening collection that have never shown biological activity despite having been exhaustively tested in HTS assays. These compounds are referred to as 'dark chemical matter' (DCM). We quantified DCM, validated it in quality control experiments, described its physicochemical properties and mapped it into chemical space. Through analysis of prospective reporter-gene assay, gene expression and yeast chemogenomics experiments, we evaluated the potential of DCM to show biological activity in future screens. We demonstrated that, despite the apparent lack of activity, occasionally these compounds can result in potent hits with unique activity and clean safety profiles, which makes them valuable starting points for lead optimization efforts. Among the identified DCM hits was a new antifungal chemotype with strong activity against the pathogen Cryptococcus neoformans but little activity at targets relevant to human safety.


Subject(s)
Antifungal Agents/pharmacology , Cryptococcus neoformans/drug effects , Drug Discovery , High-Throughput Screening Assays , Antifungal Agents/chemistry , Microbial Sensitivity Tests , Molecular Structure , Structure-Activity Relationship
12.
Nat Commun ; 6: 8613, 2015 Oct 12.
Article in English | MEDLINE | ID: mdl-26456460

ABSTRACT

FR171456 is a natural product with cholesterol-lowering properties in animal models, but its molecular target is unknown, which hinders further drug development. Here we show that FR171456 specifically targets the sterol-4-alpha-carboxylate-3-dehydrogenase (Saccharomyces cerevisiae--Erg26p, Homo sapiens--NSDHL (NAD(P) dependent steroid dehydrogenase-like)), an essential enzyme in the ergosterol/cholesterol biosynthesis pathway. FR171456 significantly alters the levels of cholesterol pathway intermediates in human and yeast cells. Genome-wide yeast haploinsufficiency profiling experiments highlight the erg26/ERG26 strain, and multiple mutations in ERG26 confer resistance to FR171456 in growth and enzyme assays. Some of these ERG26 mutations likely alter Erg26 binding to FR171456, based on a model of Erg26. Finally, we show that FR171456 inhibits an artificial Hepatitis C viral replicon, and has broad antifungal activity, suggesting potential additional utility as an anti-infective. The discovery of the target and binding site of FR171456 within the target will aid further development of this compound.


Subject(s)
3-Hydroxysteroid Dehydrogenases/antagonists & inhibitors , Antifungal Agents/chemistry , Cholesterol/analogs & derivatives , Saccharomyces cerevisiae Proteins/antagonists & inhibitors , Saccharomyces cerevisiae/genetics , 3-Hydroxysteroid Dehydrogenases/genetics , Candida albicans , Cholesterol/chemistry , Drug Resistance, Fungal/genetics , Ergosterol/biosynthesis , Mutation , Saccharomyces cerevisiae Proteins/genetics
13.
Hepatology ; 62(5): 1497-510, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26173433

ABSTRACT

UNLABELLED: The Yes-associated protein (YAP)/Hippo pathway has been implicated in tissue development, regeneration, and tumorigenesis. However, its role in cholangiocarcinoma (CC) is not established. We show that YAP activation is a common feature in CC patient biopsies and human CC cell lines. Using microarray expression profiling of CC cells with overexpressed or down-regulated YAP, we show that YAP regulates genes involved in proliferation, apoptosis, and angiogenesis. YAP activity promotes CC growth in vitro and in vivo by functionally interacting with TEAD transcription factors (TEADs). YAP activity together with TEADs prevents apoptosis induced by cytotoxic drugs, whereas YAP knockdown sensitizes CC cells to drug-induced apoptosis. We further show that the proangiogenic microfibrillar-associated protein 5 (MFAP5) is a direct transcriptional target of YAP/TEAD in CC cells and that secreted MFAP5 promotes tube formation of human microvascular endothelial cells. High YAP activity in human CC xenografts and clinical samples correlates with increased MFAP5 expression and CD31(+) vasculature. CONCLUSIONS: These findings establish YAP as a key regulator of proliferation and antiapoptotic mechanisms in CC and provide first evidence that YAP promotes angiogenesis by regulating the expression of secreted proangiogenic proteins.


Subject(s)
Bile Duct Neoplasms/pathology , Bile Ducts, Intrahepatic , Cholangiocarcinoma/pathology , DNA-Binding Proteins/physiology , Drug Resistance, Neoplasm , Neovascularization, Pathologic/etiology , Nuclear Proteins/physiology , Transcription Factors/physiology , Animals , Apoptosis , Bile Duct Neoplasms/blood supply , Bile Duct Neoplasms/drug therapy , Cell Cycle Proteins , Cell Proliferation , Cholangiocarcinoma/blood supply , Cholangiocarcinoma/drug therapy , Contractile Proteins/genetics , Female , Gene Expression Regulation, Neoplastic , Glycoproteins/genetics , Humans , Intercellular Signaling Peptides and Proteins , Mice , Oncogenes , TEA Domain Transcription Factors
14.
J Biomol Screen ; 19(5): 628-39, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24598104

ABSTRACT

Advances in instrumentation now allow the development of screening assays that are capable of monitoring multiple readouts such as transcript or protein levels, or even multiple parameters derived from images. Such advances in assay technologies highlight the complex nature of biology and disease. Harnessing this complexity requires integration of all the different parameters that can be measured rather than just monitoring a single dimension as is commonly used. Although some of the methods used to combine multiple measurements, such as principal component analysis, are commonly used for microarray analysis, biologists are not yet using many of the tools that have been developed in other fields to address such issues. Visualization of multiparametric data sets is one of the major challenges in this field, and a depiction of the results in a manner that can be readily interpreted is essential. This article describes a number of assay systems being used to generate such data sets en masse, and the methods being applied to their visualization and analysis. We also discuss some of the challenges of applying methods developed in other fields to biology.


Subject(s)
Computational Biology/methods , High-Throughput Screening Assays/methods , Algorithms , Chemistry, Pharmaceutical/methods , Datasets as Topic , Machine Learning , Phenotype , Principal Component Analysis , Proteins/chemistry , RNA/chemistry , Software
15.
J Biol Chem ; 288(38): 27434-27443, 2013 Sep 20.
Article in English | MEDLINE | ID: mdl-23940034

ABSTRACT

TLQP-21, a peptide derived from VGF (non-acronymic) by proteolytic processing, has been shown to modulate energy metabolism, differentiation, and cellular response to stress. Although extensively investigated, the receptor for this endogenous peptide has not previously been described. This study describes the use of a series of studies that show G protein-coupled receptor-mediated biological activity of TLQP-21 signaling in CHO-K1 cells. Unbiased genome-wide sequencing of the transcriptome from responsive CHO-K1 cells identified a prioritized list of possible G protein-coupled receptors bringing about this activity. Further experiments using a series of defined receptor antagonists and siRNAs led to the identification of complement C3a receptor-1 (C3AR1) as a target for TLQP-21 in rodents. We have not been able to demonstrate so far that this finding is translatable to the human receptor. Our results are in line with a large number of physiological observations in rodent models of food intake and metabolic control, where TLQP-21 shows activity. In addition, the sensitivity of TLQP-21 signaling to pertussis toxin is consistent with the known signaling pathway of C3AR1. The binding of TLQP-21 to C3AR1 not only has effects on signaling but also modulates cellular functions, as TLQP-21 was shown to have a role in directing migration of mouse RAW264.7 cells.


Subject(s)
Cell Movement/drug effects , Peptide Fragments/pharmacology , Receptors, Complement/metabolism , Signal Transduction/drug effects , Animals , Base Sequence , CHO Cells , Cricetinae , Cricetulus , Genome-Wide Association Study , HEK293 Cells , Humans , Mice , Molecular Sequence Data , Nerve Growth Factors/pharmacology , Neuropeptides/pharmacology , Pertussis Toxin/pharmacology , Rats , Receptors, Complement/agonists , Receptors, Complement/genetics , Species Specificity , Transcriptome/drug effects
16.
Assay Drug Dev Technol ; 11(6): 355-66, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23906347

ABSTRACT

The use of small molecules to modulate cellular processes is a powerful approach to investigate gene function as a complement to genetic approaches. The discovery and characterization of compounds that modulate translation initiation, the rate-limiting step of protein synthesis, is important both to provide tool compounds to explore this fundamental biological process and to further evaluate protein synthesis as a therapeutic target. While most messenger ribonucleic acids (mRNAs) recruit ribosomes via their 5' cap, some viral and cellular mRNAs initiate protein synthesis via an alternative "cap-independent" mechanism utilizing internal ribosome entry sites (IRES) elements, which are complex mRNA secondary structures, localized within the 5' nontranslated region of the mRNA upstream of the AUG start codon. This report describes the design of a functional, high throughput screen of small molecules miniaturized into a 1,536-well format and performed using the luciferase reporter gene under control of the viral Cardiovirus encephalomyocarditis virus (EMCV) IRES element to identify nontoxic compounds modulating translation initiated from the EMCV IRES. One activating compound, validated in a dose response manner, has previously been shown to bind the glucocorticoid receptor (GR). Subsequent testing of additional GR modulators further supported this as the possible mechanism of action. Detailed characterization of this compound activity supported the notion that this was due to an effect at the level of translation.


Subject(s)
Encephalomyocarditis virus/drug effects , Protein Biosynthesis/drug effects , Receptors, Glucocorticoid/drug effects , Ribosomes/virology , Virus Internalization/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Drug Design , Encephalomyocarditis virus/physiology , High-Throughput Screening Assays , Humans , Ligands , Receptors, Glucocorticoid/physiology
17.
J Biomol Screen ; 18(4): 407-19, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23150017

ABSTRACT

Translation initiation is a fine-tuned process that plays a critical role in tumorigenesis. The use of small molecules that modulate mRNA translation provides tool compounds to explore the mechanism of translational initiation and to further validate protein synthesis as a potential pharmaceutical target for cancer therapeutics. This report describes the development and use of a click beetle, dual luciferase cell-based assay multiplexed with a measure of compound toxicity using resazurin to evaluate the differential effect of natural products on cap-dependent or internal ribosome entry site (IRES)-mediated translation initiation and cell viability. This screen identified a series of cardiac glycosides as inhibitors of IRES-mediated translation using, in particular, the oncogene mRNA c-Myc IRES. Treatment of c-Myc-dependent cancer cells with these compounds showed a decrease in c-Myc protein associated with a significant modulation of cell viability. These findings suggest that inhibition of IRES-mediated translation initiation may be a strategy to inhibit c-Myc-driven tumorigenesis.


Subject(s)
Cardiac Glycosides/analysis , Cardiac Glycosides/pharmacology , Drug Evaluation, Preclinical , Protein Biosynthesis/drug effects , Protein Synthesis Inhibitors/pharmacology , Proto-Oncogene Proteins c-myc/metabolism , Ribosomes/metabolism , Apoptosis/drug effects , Base Sequence , Biological Assay , Cardiac Glycosides/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Cymarine/chemistry , Cymarine/pharmacology , DNA Damage , Genes, Reporter , HEK293 Cells , Humans , Inhibitory Concentration 50 , Protein Synthesis Inhibitors/analysis , Protein Synthesis Inhibitors/chemistry , Proto-Oncogene Proteins c-myc/antagonists & inhibitors , Ribosomes/drug effects , Vascular Endothelial Growth Factor A/metabolism
18.
PLoS One ; 7(7): e40976, 2012.
Article in English | MEDLINE | ID: mdl-22815884

ABSTRACT

The Wnt/ß-catenin signaling pathbway controls many important biological processes. R-Spondin (RSPO) proteins are a family of secreted molecules that strongly potentiate Wnt/ß-catenin signaling, however, the molecular mechanism of RSPO action is not yet fully understood. We performed an unbiased siRNA screen to identify molecules specifically required for RSPO, but not Wnt, induced ß-catenin signaling. From this screen, we identified LGR4, then an orphan G protein-coupled receptor (GPCR), as the cognate receptor of RSPO. Depletion of LGR4 completely abolished RSPO-induced ß-catenin signaling. The loss of LGR4 could be compensated by overexpression of LGR5, suggesting that LGR4 and LGR5 are functional homologs. We further demonstrated that RSPO binds to the extracellular domain of LGR4 and LGR5, and that overexpression of LGR4 strongly sensitizes cells to RSPO-activated ß-catenin signaling. Supporting the physiological significance of RSPO-LGR4 interaction, Lgr4-/- crypt cultures failed to grow in RSPO-containing intestinal crypt culture medium. No coupling between LGR4 and heterotrimeric G proteins could be detected in RSPO-treated cells, suggesting that LGR4 mediates RSPO signaling through a novel mechanism. Identification of LGR4 and its relative LGR5, an adult stem cell marker, as the receptors of RSPO will facilitate the further characterization of these receptor/ligand pairs in regenerative medicine applications.


Subject(s)
Receptors, G-Protein-Coupled/metabolism , Thrombospondins/physiology , Wnt Proteins/metabolism , beta Catenin/metabolism , DNA, Complementary/metabolism , GTP-Binding Proteins/metabolism , HEK293 Cells , Humans , Intestinal Mucosa/metabolism , Ligands , Models, Biological , Open Reading Frames , Protein Structure, Tertiary , RNA Interference , RNA, Small Interfering/metabolism , Signal Transduction , Stem Cells/cytology
19.
Antimicrob Agents Chemother ; 56(8): 4233-40, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22615293

ABSTRACT

Systemic life-threatening fungal infections represent a significant unmet medical need. Cell-based, phenotypic screening can be an effective means of discovering potential novel antifungal compounds, but it does not address target identification, normally required for compound optimization by medicinal chemistry. Here, we demonstrate a combination of screening, genetic, and biochemical approaches to identify and characterize novel antifungal compounds. We isolated a set of novel non-azole antifungal compounds for which no target or mechanism of action is known, using a screen for inhibition of Saccharomyces cerevisiae proliferation. Haploinsufficiency profiling of these compounds in S. cerevisiae suggests that they target Erg11p, a cytochrome P450 family member, which is the target of azoles. Consistent with this, metabolic profiling in S. cerevisiae revealed a buildup of the metabolic intermediates prior to Erg11p activity, following compound treatment. Further, human cytochrome P450 is also inhibited in in vitro assays by these compounds. We modeled the Erg11p protein based on the human CYP51 crystal structure, and in silico docking of these compounds suggests that they interact with the heme center in a manner similar to that of azoles. Consistent with these docking observations, Candida strains carrying azole-resistant alleles of ERG11 are also resistant to the compounds in this study. Thus, we have identified non-azole Erg11p inhibitors, using a systematic approach for ligand and target characterization.


Subject(s)
Antifungal Agents/pharmacology , Cytochrome P-450 Enzyme Inhibitors , Saccharomyces cerevisiae Proteins/antagonists & inhibitors , Saccharomyces cerevisiae/drug effects , Antifungal Agents/chemistry , Azoles/pharmacology , Cytochrome P-450 Enzyme System , Drug Resistance, Fungal/genetics , High-Throughput Screening Assays , Microbial Sensitivity Tests , Models, Molecular , Protein Structure, Quaternary , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism
20.
J Biomol Screen ; 17(6): 843-9, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22396475

ABSTRACT

High-throughput screening, based on subcellular imaging, has become a powerful tool in lead discovery. Through the generation of high-quality images, not only the specific target signal can be analyzed but also phenotypic changes of the whole cell are recorded. Yet analysis strategies for the exploration of high-content screening results, in a manner that is independent from predefined control phenotypes, are largely missing. The approach presented here is based on a well-established modeling technique, self-organizing maps (SOMs), which uses multiparametric results to group treatments that create similar morphological effects. This report describes a novel visualization of the SOM clustering by using an image of the cells from each node, with the most representative cell highlighted to deploy the phenotype described by each node. The approach has the potential to identify both expected hits and novel cellular phenotypes. Moreover, different chemotypes, which cause the same phenotypic effects, are identified, thus facilitating "scaffold hopping."


Subject(s)
Drug Evaluation, Preclinical/methods , High-Throughput Screening Assays/methods , Image Processing, Computer-Assisted/methods , Laser Scanning Cytometry/methods , Animals , CHO Cells , Cluster Analysis , Cricetinae , Cricetulus , Cystic Fibrosis Transmembrane Conductance Regulator/agonists , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Laser Scanning Cytometry/instrumentation , Multivariate Analysis , Phenotype , Principal Component Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...